A role for the transducer of the Hippo pathway, TAZ, in the development of aggressive types of endometrial cancer

Modern Pathology

Volumn 28, Issue 11, 2015, Pages 1492-1503

  Romero Pérez, Laura ^a   Garcia Sanz, Pablo ^b,c   Mota, Alba ^b,c   Leskelä, Susanna ^d   Hergueta Redondo, Marta ^b   Díaz Martín, Juan ^a   López García, M Angeles ^a   Castilla, M Angeles ^a   Martínez Ramírez, Angel ^c   Soslow, Robert A ^e   Matias Guiu, Xavier ^f   Moreno Bueno, Gema ^b,c,g   Palacios, Jose ^a,d  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^b INSTITUTO DE INVESTIGACIONES BIOMÉDICAS ALBERTO SOLS   (Spain)

^c MD ANDERSON CANCER CENTER   (Spain)

^d HOSPITAL RAMÓN Y CAJAL   (Spain)

^e MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^f HOSPITAL UNIVERSITARI ARNAU DE VILANOVA   (Spain)

^g UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CLAUDIN 1; FIZZY RELATED PROTEIN; HEAT SHOCK PROTEIN 90; HIGH MOBILITY GROUP A2 PROTEIN; HIPPO PROTEIN; MESSENGER RNA; MICRORNA; NERVE CELL ADHESION MOLECULE; OSTEONECTIN; TAZ PROTEIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR 7 LIKE 1; TRANSCRIPTION FACTOR SLUG; TRANSCRIPTION FACTOR ZEB1; TRANSCRIPTION FACTOR ZEB2; UNCLASSIFIED DRUG; UVOMORULIN; VIMENTIN; HIPPO PROTEIN, HUMAN; PROTEIN SERINE THREONINE KINASE; TAZ PROTEIN, HUMAN;

ARTICLE; CANCER GROWTH; CELL MOTILITY; ENDOMETRIOID CARCINOMA; ENDOMETRIUM CANCER; ENDOMETRIUM CARCINOMA; ENDOMETRIUM CARCINOSARCOMA; ENDOMETRIUM SEROUS CARCINOMA; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MASS SPECTROMETRY; METHYLATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; ANIMAL; CARCINOMA; CELL MOTION; CELL PROLIFERATION; DNA MICROARRAY; ENDOMETRIUM TUMOR; FLUORESCENT ANTIBODY TECHNIQUE; METABOLISM; MOUSE; PATHOLOGY; PHYSIOLOGY; POLYMERASE CHAIN REACTION; WESTERN BLOTTING; XENOGRAFT;

ANIMALS; BLOTTING, WESTERN; CARCINOMA; CELL MOVEMENT; CELL PROLIFERATION; ENDOMETRIAL NEOPLASMS; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; HETEROGRAFTS; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; MASS SPECTROMETRY; MICE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; POLYMERASE CHAIN REACTION; PROTEIN-SERINE-THREONINE KINASES; TRANSCRIPTION FACTORS;

EID: 84946489066     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2015.102     Document Type: Article

References (41)

1. Allard JE, Maxwell GL. Race disparities between black and white women in the incidence, treatment, and prognosis of endometrial cancer. Cancer Control 2009;16: 53-56.
2. López-García MA, Vieites MB, Castilla MA et al. Genetics of endometrial carcinoma. In: Ulrich P (ed). Cancer Genomics: Molecular Classification, Prognosis and Response Prediction, 1st edition. Springer Science and Business Media: Dordrecht. 2013;11:390.
3. Castilla MA, Moreno-Bueno G, Romero-Perez L et al. Micro-RNA signature of the epithelial-mesenchymal transition in endometrial carcinosarcoma. J Pathol 2011;223:72-80.
4. Romero-Perez L, Lopez-Garcia MA, Diaz-Martin J et al. ZEB1 overexpression associated with E-cadherin and microRNA-200 downregulation is characteristic of undifferentiated endometrial carcinoma. Mod Pathol 2013;26:1514-1524.
5. Mirantes C, Espinosa I, Ferrer I et al. Epithelial-tomesenchymal transition and stem cells in endometrial cancer. Hum Pathol 2013;44:1973-1981.
6. Colas E, Pedrola N, Devis L et al. The EMT signaling pathways in endometrial carcinoma. Clin Transl Oncol 2012;14:715-720.
7. Mani SA, Guo W, Liao MJ et al. The epithelialmesenchymal transition generates cells with properties of stem cells. Cell 2008;133:704-715.
8. Puisieux A, Brabletz T, Caramel J. Oncogenic roles of EMT-inducing transcription factors. Nat Cell Biol 2014;16:488-494.
9. De Craene B, Berx G. Regulatory networks defining EMT during cancer initiation and progression. Nat Rev Cancer 2013;13:97-110.
10. Morel AP, Lievre M, Thomas C et al. Generation of breast cancer stem cells through epithelialmesenchymal transition. PLoS One 2008;3:e2888.
11. Brabletz T, Jung A, Spaderna S et al. Opinion: migrating cancer stem cells-an integrated concept of malignant tumour progression. Nat Rev Cancer 2005;5: 744-749.
12. Moroishi T, Hansen CG, Guan KL. The emerging roles of YAP and TAZ in cancer. Nat Rev Cancer 2015;15: 73-79.
13. Hiemer SE, Varelas X. Stem cell regulation by the Hippo pathway. Biochim Biophys Acta 2013;1830:2323-2334.
14. Mo JS, Park HW, Guan KL. The Hippo signaling pathway in stem cell biology and cancer. EMBO Rep 2014;15:642-656.
15. Diepenbruck M, Waldmeier L, Ivanek R et al. Tead2 expression levels control the subcellular distribution of Yap and Taz, zyxin expression and epithelial-mesenchymal transition. J Cell Sci 2014;127:1523-1536.
16. Lei QY, Zhang H, Zhao B et al. TAZ promotes cell proliferation and epithelial-mesenchymal transition and is inhibited by the hippo pathway. Mol Cell Biol 2008;28:2426-2436.
17. Kanai F, Marignani PA, Sarbassova D et al. TAZ: a novel transcriptional co-activator regulated by interactions with 14-3-3 and PDZ domain proteins. EMBO J 2000;19:6778-6791.
18. Cordenonsi M, Zanconato F, Azzolin L et al. The Hippo transducer TAZ confers cancer stem cell-related traits on breast cancer cells. Cell 2011;147:759-772.
19. Piccolo S, Cordenonsi M, Dupont S. Molecular pathways: YAP and TAZ take center stage in organ growth and tumorigenesis. Clin Cancer Res 2013;19: 4925-4930.
20. Liu Y, Xin Y, Ye F et al. Taz-tead1 links cell-cell contact to zeb1 expression, proliferation, and dedifferentiation in retinal pigment epithelial cells. Invest Ophthalmol Vis Sci 2010;51:3372-3378.
21. Romero-Perez L, Castilla MA, Lopez-Garcia MA et al. Molecular events in endometrial carcinosarcomas and the role of high mobility group AT-hook 2 in endometrial carcinogenesis. Hum Pathol 2013;44:244-254.
22. Kononen J, Bubendorf L, Kallioniemi A et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998;4:844-847.
23. Zordan A. Fluorescence in situ hybridization on formalin-fixed, paraffin-embedded tissue sections. Methods Mol Biol 2011;730:189-202.
24. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001;25: 402-408.
25. Moreno-Bueno G, Peinado H, Molina P et al. The morphological and molecular features of the epithelialto-mesenchymal transition. Nat Protoc 2009;4:1591-1613.
26. Franci C, Takkunen M, Dave N et al. Expression of Snail protein in tumor-stroma interface. Oncogene 2006;25:5134-5144.
27. Bhat KP, Salazar KL, Balasubramaniyan V et al. The transcriptional coactivator TAZ regulates mesenchymal differentiation in malignant glioma. Genes Dev 2011;25:2594-2609.
28. Yang N, Morrison CD, Liu P et al. TAZ induces growth factor-independent proliferation through activation of EGFR ligand amphiregulin. Cell Cycle 2012;11: 2922-2930.
29. Liu C, Huang W, Lei Q. Regulation and function of the TAZ transcription co-activator. Int J Biochem Mol Biol 2011;2:247-256.
30. de Cristofaro T, Di Palma T, Ferraro A et al. TAZ/ WWTR1 is overexpressed in papillary thyroid carcinoma. Eur J Cancer 2011;47:926-933.
31. Koutsaki M, Spandidos DA, Zaravinos A. Epithelialmesenchymal transition-associated miRNAs in ovarian carcinoma, with highlight on the miR-200 family: prognostic value and prospective role in ovarian cancer therapeutics. Cancer Lett 2014;351:173-181.
32. Diaz-Lopez A, Moreno-Bueno G, Cano A. Role of microRNA in epithelial to mesenchymal transition and metastasis and clinical perspectives. Cancer Manag Res 2014;6:205-216.
33. Hua Y, Duan S, Murmann AE et al. miRConnect: identifying effector genes of miRNAs and miRNA families in cancer cells. PLoS One 2011;6:e26521.
34. Varelas X, Sakuma R, Samavarchi-Tehrani P et al. TAZ controls Smad nucleocytoplasmic shuttling and regulates human embryonic stem-cell self-renewal. Nat Cell Biol 2008;10:837-848.
35. Chan SW, Lim CJ, Guo K et al. A role for TAZ in migration, invasion, and tumorigenesis of breast cancer cells. Cancer Res 2008;68:2592-2598.
36. Dong J, Feldmann G, Huang J et al. Elucidation of a universal size-control mechanism in Drosophila and mammals. Cell 2007;130:1120-1133.
37. Zhang Y, Martens JW, Yu JX et al. Copy number alterations that predict metastatic capability of human breast cancer. Cancer Res 2009;69:3795-3801.
38. Kodaka M, Hata Y. The mammalian Hippo pathway: regulation and function of YAP1 and TAZ. Cell Mol Life Sci 2014;72:285-306.
39. Zhao B, Wei X, Li W et al. Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. Genes Dev 2007;21:2747-2761.
40. Ouyang Z, Zhan W, Dan L. hScrib, a human homolog of Drosophila neoplastic tumor suppressor, is involved in the progress of endometrial cancer. Oncol Res 2010;18: 593-599.
41. Halaoui R, McCaffrey L. Rewiring cell polarity signaling in cancer. Oncogene 2014;34:939-950.